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Abstract
Objectives—As evidence suggests visit-to-visit variability (VVV) of blood pressure (BP) is
associated with cardiovascular events and mortality, there is increasing interest in identifying
interventions that reduce VVV of BP. We investigated the effects of weight loss and sodium
reduction, alone or in combination, on VVV of BP in participants enrolled in phase II of the Trials
of Hypertension Prevention.
Methods—BP readings were taken at 6-month intervals for 36 months in 1,820 participants with
high-normal diastolic BP (DBP) who were randomized to weight loss, sodium reduction,
combination (weight loss and sodium reduction), or usual care groups. VVV of BP was defined as
the standard deviation of BP across 6 follow-up visits.
Results—VVV of systolic BP (SBP) was not significantly different between participants
randomized to the weight loss (7.2 ± 3.1 mmHg), sodium reduction (7.1 ± 3.0 mmHg), or
combined (6.9 ± 2.9 mmHg) intervention groups vs. the usual care group (6.9 ± 2.9 mmHg). In a
fully adjusted model, no difference (0.0 ± 0.2 mmHg) in VVV of SBP was present between
individuals who successfully maintained their weight loss versus individuals who did not lose
weight during follow-up (p=0.93). Also, those who maintained a reduced sodium intake
throughout follow-up did not have lower VVV of SBP compared to those who did not reduce their
sodium intake (0.1 ± 0.3 mmHg; p=0.77). Results were similar for VVV of DBP.
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Conclusions—These findings suggest that weight loss and sodium reduction may not be
effective interventions for lowering VVV of BP in individuals with high-normal DBP.
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INTRODUCTION
Evidence has accumulated to show that visit-to-visit variability (VVV) of blood pressure
(BP) is associated with cardiovascular events including stroke, coronary heart disease, and
mortality1–5. The association between VVV of BP and these outcomes is independent of
several potential confounders including mean BP. A reduction in mean BP has been the
principal target of antihypertensive therapy for decades. However, recent evidence suggests
that specific classes of antihypertensive medications lower VVV of BP and this reduction in
VVV of BP has been linked to a lower stroke risk, independent of treatment effects on mean
BP6.
Recommendations for the control of high BP emphasize lifestyle modification, including
weight loss and reduction of sodium intake7. These recommendations stem from a
substantial and largely consistent body of evidence from randomized controlled trials that
have documented that lifestyle interventions reduce mean BP, with the most recent meta-
analyses reporting that weight loss and sodium intake reduction lower mean systolic BP
(SBP) by 4.9 and 5.0 mmHg, respectively, and mean diastolic BP (DBP) by 2.7 and 4.9
mmHg, respectively8,9. Although the beneficial effects of lifestyle interventions on mean BP
are well established, scant attention has been paid to the efficacy of non-pharmacologic
treatment modalities on VVV of BP. The purpose of this study, therefore, was to investigate
the effects of weight loss and sodium intake reduction on VVV of BP using data collected
from phase II of the Trials of Hypertension Prevention (TOHP II), a randomized controlled
trial that examined the BP lowering effects of weight loss and sodium reduction, alone and
in combination, in overweight adults with high-normal DBP10.
METHODS
Study Design
Details of TOHP II study design, recruitment, and methodology have been previously
described10–13. Briefly, TOPH II was a multicenter, randomized controlled trial of 2,382
participants randomly assigned to one of four treatment groups: weight loss alone, sodium
reduction alone, combined weight loss and sodium reduction, or usual care for 36–48
months. The TOHP II clinical centers included locations across the U.S.: Baltimore, MD;
Birmingham, AL; Davis, CA; Jackson, MS; Memphis, TN; Newark, NJ; Portland, OR;
Pittsburgh, PA; and St. Louis, MO. All participants provided written informed consent. This
secondary analysis used public access data from TOHP II and was approved by the
institutional review board at Columbia University Medical Center.
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For inclusion, participants were required to be 30–54 years of age, have a DBP of 83–89
mmHg and a SBP <140 mmHg, and have a body mass index (BMI) of 26.1–37.4 kg/m2 for
men and 24.4–37.4 kg/m2 for women. Exclusion criteria included: active treatment with
antihypertensive medication or use of medication that affects BP, cardiovascular disease,
diabetes, renal insufficiency, alcohol intake >21 drinks/week, chronic and/or life-threatening
illness requiring regular medical treatment, and current/planned pregnancy.
Intervention
The structure and content of the weight loss and sodium reduction interventions have been
previously described12. Briefly, the first 10–14 weeks of the intervention consisted of an
intensive intervention stage with weekly group counseling. This stage was followed by a
transitional phase designed to prevent relapse and ease the transition from weekly to less
frequent contact with intervention staff and consisted of 4–6 biweekly sessions. After the
transitional phase, participants entered a final extended stage which lasted through 36
months post-randomization for the purposes of maintaining participants’ behavior changes.
Average weight loss at 6 months was −4.5 ± 0.3 kg and −4.3 ± 0.3 kg in the weight loss and
combined intervention groups, respectively, compared to the usual care group. Also at 6
months, average reductions in urinary sodium excretion in the sodium reduction and
combined intervention groups was −50.4 ± 13.8 mmol/d and −36.7 ± 13.3 mmol/day,
respectively, compared to the usual care group13.
Overview of Study Measures
Three screening visits were conducted prior to randomization. During these visits,
sociodemographic characteristics (age, sex, race/ethnicity, education, employment status)
and health habits (cigarette smoking, alcohol consumption, physical activity) were obtained
by questionnaire. BP, heart rate (HR), and anthropometric measurements were obtained at
clinic visits during screening. Participants also provided a 24-hour urine sample which was
analyzed for sodium and potassium excretion.
Follow-up visits were conducted at 6-month intervals following randomization for 36
months. Weight, BP, HR, and medication use information were recorded at every follow-up
visit. Twenty-four hour urine samples were collected during the 18- and 36-month visits. All
measures were obtained by trained staff, blinded to group assignment.
BP Measurement and Definitions of VVV
Figure 1 shows when BP measurements were obtained in TOPH II (upper panel). BP was
measured at the three screening visits (baseline) which were each separated by a period of
7–45 days (median intervals: 14 days between visits 1 and 2; 15 days between visits 2 and
3). During follow-up, BP measurements were obtained at three separate visits at 7–10-day
intervals at the 18- and 36-month follow-up periods. BP was obtained during a single visit at
all other follow-up periods (6-, 12-, 24-, and 30-month visits). For each visit, three BP
readings were obtained in the seated position after 5 minutes of rest by trained staff blinded
to the randomization assignment using a random-zero sphygmomanometer and an
appropriately sized arm cuff. The average of the three measurements was used as the BP for
each visit. Study visits were scheduled on non-exercise days and every effort was taken to
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measure BP during follow-up visits at the same time of day as when the baseline visit
occurred. To minimize measurement variability across BP observers, uniform training
(minimum of 4–5 half-day training sessions) and certification of BP observer were required
and recertification was performed at 6-month intervals. To ensure high quality data, a data
collection and quality assurance subcommittee reviewed the performance of each clinical
center at regular intervals. BP data were monitored for digit preference, error on data
collection forms, and protocol compliance. At least one site visit to assess protocol
compliance was made to each clinical center, with additional visits conducted on an as-
needed basis.
For primary analyses (middle panel, Figure 1), VVV of BP was expressed as the standard
deviation (SD) of BP across the six visits from the 6-month though the 36-month follow-up
visit (VVVFU). The pre-randomization BP measurements were not included in this
calculation of VVV in order to avoid the variability caused by the initial reduction in BP
attributable to the intervention. Also, as duration of time between visits affects VVV of BP
and to keep between-visit intervals relatively fixed, we only used BP measurements from the
first of the three 18-month and 36-month visits for calculation of VVVFU14. In secondary
analyses (lower panel, Figure 1), VVV of BP was expressed as the SD of BP using visits
performed at shorter intervals: across the three screening visits (VVVbaseline), the three visits
at 18 months (VVV18mo), and the three visits at 36 months (VVV36mo). Other metrics of
VVV of BP, such as coefficient of variation and variation independent of the mean, were not
included in the analyses as these metrics are highly correlated with SD (r > 0.97) and
therefore represent the same domain of VVV of BP15.
Statistical Analysis
Analyses were restricted to participants who had three BP readings at every visit through 36
months (n=1820). Participants excluded from analyses (n=562) were younger, less likely to
be married, less likely to be a college graduate, more often current smokers, more likely to
consume alcohol, had a higher weight and BMI, and had lower potassium excretion
compared to participants included in the current analyses (Supplemental Table 1).
Differences in clinical characteristics were estimated between randomization groups using
χ2-tests for categorical variables and analysis of variance (ANOVA) for continuous
variables. In order to replicate the original TOHP findings for mean BP13 in this restricted
sample, the effect of the interventions on mean BP at each follow-up visit was calculated
and differences in the changes were assessed using one-way ANOVA followed by post hoc
testing with the Fisher’s least significance test for differences between each intervention
group and the usual care group. ANOVA and analysis of covariance (ANCOVA) was used
to assess unadjusted and adjusted differences, respectively, in VVVFU of BP between each
active intervention group with the usual care group serving as the referent. Initial models
included adjustment for age, sex, and race/ethnicity (model 1). Subsequent models included
additional adjustment for newly started antihypertensive medication usage during follow-up
(model 2) and mean BP at the 18-month visit (model 3), the first visit that BP was measured
after the intensive intervention stage for intervention participants. Mean BP at 18 months
was chosen as a covariate because of the reduced efficacy of the interventions on mean BP
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during the transitional phase and the extended stage that was observed in TOPH II13. Our
aim in model 3 was to examine the effects of the interventions versus usual care on VVV of
BP, independent of significant intervention-related reductions in mean BP, which occurred
at 18 months. Next, two-way repeated measures ANOVA and ANCOVA were used to
examine the effect of randomization on the change in VVV of BP based on the three
baseline, 18-month and 36-month visits (VVVbaseline, VVV18mo, and VVV36mo). Models
with progressive adjustment as described above were conducted. All analyses were
performed for SBP and DBP, separately. In a sensitivity analysis, to further account for the
effect of newly started antihypertensive medication, we repeated primary analyses excluding
individuals who started on antihypertensive medication during follow-up (n=256; 14.1% of
study sample). In a separate sensitivity analysis, primary analyses were repeated adjusting
for mean BP over the follow-up period in model 3 instead of mean BP at 18 months. Finally,
in a third sensitivity analysis, VVVFU of BP was calculated over the three visits during the
first half of the trial (6 months, 12 months, and 18 months) when the greatest effects on
mean BP were observed.
For secondary analyses, the effects of achieved weight loss and sodium reduction over time
on VVV of BP were examined, separately, at the within-subject level, using criteria defined
previously16,17. Participants were stratified into three groups according to patterns of
achieved weight loss: (1) participants with successful maintenance of weight loss were
defined as those who lost 4.5 kg or more at 6 months and maintained at least 4.5 kg of
weight loss at 36 months; (2) participants who relapsed were those who lost at least 4.5 kg at
6 months but whose weight loss at 36 months was less than 2.5 kg; and (3) participants with
no weight loss were defined as those who had weight loss of 2.5 kg or less at 6 and 36
months (referent group). Next, participants were stratified into 4 groups according to their
achieved 24-hour sodium excretion levels: (1) maintainers were defined as those who
decreased their sodium excretion levels from baseline by at least 50 mmol/24-hour at 18 and
36 months and who had a sodium excretion level of 104 mmol/24-hour or lower at 18 and
36 months; (2) participants who relapsed were defined as those who achieved these criteria
at 18 but not 36 months; (3) improvers were considered those who achieved these criteria at
36 months but not at 18 months; and (4) no success was defined as those who did not
achieve these criteria at either follow-up period (referent group). For these secondary
analyses, an initial model included adjustment for age, sex, race/ethnicity, and
randomization to a sodium reduction intervention group (for analysis of weight loss success
categories) or randomization to a weight loss intervention group (for analysis of sodium
reduction success categories; model 1). Subsequent models included additional adjustment
for newly started antihypertensive medication usage, current smoking, and alcohol use
(model 2); and mean BP and HR at 18 months (model 3).
P-values <0.05 were considered statistically significant. Analyses were performed using
SPSS version 18.0 (SPSS, Chicago, IL).
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The study population consisted of 1820 participants with complete BP data, including 1209
males (66%) and 611 females (33%). Mean age was 43.9 ± 6.1 years and mean BMI was
30.8 ± 3.1 kg/m2. Among the study population, 16.9% (n=307) were black, 52.7% (n=960)
were college graduates, 8.2% (n=149) were current smokers, and 88.5% (n=1610) were
employed full-time. Mean SBP and DBP were 127.5 ± 6.3 mmHg and 86.0 ± 2.0 mmHg,
respectively. Of the study population, 87.4% (n=1591) had SBP levels in the
prehypertensive range (≥ 120 mmHg). Table 1 shows the characteristics of participants
according to randomization assignment. There were no statistically significant differences
between the groups.
Effect of Interventions on Mean BP
Compared with participants in the usual care group, mean SBP and DBP significantly
decreased more in participants assigned to each active intervention group during the follow-
up period up to and including the 18-month visit. After this time, almost no significant
differences were observed (Supplemental Table 2).
Effect of Interventions on VVV of BP
There were no significant differences in VVVFU of SBP or DBP for participants in any of
the active intervention groups compared to participants in the usual care group in unadjusted
or adjusted models (Table 2). When VVV of BP was quantified using visits performed at
shorter intervals at baseline (VVVbaseline), 18 months (VVV18mo), and 36 months
(VVV36mo), VVV of SBP and DBP were not significantly different between any of the
groups in unadjusted and fully adjusted models (Table 3).
In sensitivity analyses, all results for either metric of VVV of BP were similar after
excluding participants who newly started antihypertensive medication during follow-up, and
separately after adjusting for mean BP over follow-up in model 3 instead of 18-month BP
(results not shown). Results were also similar when VVVFU of BP was quantified over the
three visits from 6 months to 18 months (results not shown).
Effects of Achieved Weight Loss on VVV
The online Supplement describes the changes in weight in achieved weight loss groups
(Supplemental Figure 1). For the successful weight loss maintenance group, VVVFU of SBP
and DBP were both significantly lower when compared to the no weight loss group in
unadjusted models (Table 4). However, these differences were no longer significant in
adjusted models. In contrast, in unadjusted and adjusted models, the relapse group had
significantly higher VVVFU of SBP and DBP when compared to the no weight loss group.
In an exploratory analysis, the association between VVVFU in body weight (defined as the
SD in body weight across follow-up visits) and VVVFU of BP was then examined among
the entire study sample. After adjustment for age, sex, race/ethnicity, randomization
assignment, newly started antihypertensive medication usage, current smoking, alcohol use,
mean BP at 18 months, mean HR at 18 months, and mean body weight over follow-up, each
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1 kg higher VVVFU in body weight was associated with a 0.13 ± 0.02 mm Hg higher
VVVFU of SBP (p < 0.001) and 0.07 ± 0.01 mm Hg higher VVVFU of DBP (p<0.001).
When VVV of BP was quantified at baseline (VVVbaseline), 18 months (VVV18mo), and 36
months (VVV36mo), VVV of SBP did not significantly differ over time between any of the
groups (time × group interaction) in unadjusted and fully adjusted models (Supplemental
Table 4). In an unadjusted model, VVV of DBP did significantly differ over time between
the groups (time × group interaction). VVV of DBP progressively increased in both the
relapse and no weight loss groups from baseline to the 18- and 36-month follow-up periods,
while it initially increased from baseline at the 18-month follow-up period and subsequently
decreased at the 36-month follow-up period in the successful maintenance group.
Effects of Achieved Sodium Reduction on VVV
The online Supplement describes the changes in 24-hour sodium excretion in achieved
sodium reduction groups (Supplemental Figure 2). In unadjusted or adjusted models, there
were no significant differences in VVVFU of SBP for the maintainers, improvers, and
relapsers compared to the no success group (Supplemental Table 4). VVVFU of DBP was
significantly higher in the improvers compared to the no success group. However, this
difference was no longer significant in a fully adjusted model. There were no differences in
VVVFU of DBP in unadjusted and fully adjusted models for the maintainers or relapsers
compared to the no success group. In an exploratory analysis, there were no significant
associations of VVVFU of sodium excretion (defined as SD across follow-up visits) with
either VVVFU of SBP or VVVFU of DBP (results not shown).
When VVV of BP was quantified at baseline (VVVbaseline), 18 months (VVV18mo), and 36
months (VVV36mo), VVV of SBP and DBP did not significantly differ over time between
any of the groups (time × group interaction) in unadjusted and fully adjusted models
(Supplemental Table 5).
DISCUSSION
In this analysis of overweight adults with high-normal DBP enrolled in TOHP II, we report
on the effects of lifestyle interventions on VVV of BP and show that there were no
differences in VVV of BP over a 36-month follow-up period between individuals
randomized to a weight loss, sodium reduction, or combined intervention group compared to
a usual care group despite intervention-related reductions in mean BP. These findings were
observed even after excluding participants who newly started antihypertensive medication
during follow-up. Furthermore, in secondary analyses, VVV of BP in individuals who
successfully maintained their weight loss or sodium reduction for the duration of the
intervention period was similar to that of individuals who did not lose weight or reduce their
sodium intake. Overall, these findings provide evidence that weight loss and sodium
reduction, alone or in combination, may not be effective interventions for reducing VVV of
BP in overweight adults with high-normal DBP.
Recently, analyses of several clinical trials have highlighted the potential importance of
lowering VVV of BP4,6,18. In the ASCOT-BPLA trial, it was found that the lower stroke and
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coronary event rates in an amlodipine-based treatment group compared with an atenolol-
based treatment group could be explained by reductions in VVV of BP4,6. Furthermore, in
the Medical Research Council (MRC) trial, it was found that risk of stroke in the atenolol
treatment group followed the same time course as changes in VVV of BP6. In a meta-
analysis of 389 clinical trials whereby inter-individual variance of BP was used as a
surrogate for VVV of BP, it was found that the effects of treatment on inter-individual
variance in BP accounted for more of the effects of treatment on stroke risk than did mean
BP18. Taken together, these studies suggest that some of the benefits of pharmacologic BP-
lowering may be mediated, in part, by their effects on VVV of BP, leading some to suggest
that VVV of BP should be targeted in intervention studies19. Current guidelines recommend
that lifestyle modifications should be adopted for the treatment of prehypertension and in
conjunction with drug therapy for stage 1 and 2 hypertension. Therefore, an understanding
of the effects that lifestyle modifications have on VVV of BP in addition to their effects on
mean BP is warranted.
Lifestyle modifications have been demonstrated to reduce mean BP, prevent or delay the
incidence of hypertension, enhance antihypertensive drug efficacy, and decrease
cardiovascular risk20. Although the present study findings do not support a role of lifestyle
modification in reducing VVV of BP, these findings do not detract from the importance of
healthy lifestyle promotion for BP management. Similar to the effects of each active
intervention on mean BP reported in the full TOHP II study sample13, we report that the
interventions were successful in the short-term at reducing mean BP with within-arm
reductions in SBP and DBP of 5.6–6.9 mmHg and 4.5–6.0 mmHg at 6-months follow-up,
respectively. The effect sizes were similar to that of within-arm reductions reported after 6-
months in non-hypertensives enrolled in other lifestyle modification trials including the
PREMIER trial (SBP/DBP reductions: 5–9/3–5 mmHg), the Hypertension Prevention Trial
(SBP/DBP reductions: 3–6/3-–5 mmHg), and phase I of TOHP (SBP/DBP reductions: 5–
6/5–6 mmHg)21–24.
In previous studies, the effectiveness of lifestyle interventions for BP reduction declined
over time21–23. These findings highlight a limitation of lifestyle interventions in that the
efficacy of weight loss and sodium reduction is attenuated with time25, 26. In the TOPH II
study, the difference in BP between groups was greatest at the end of the active intervention
phase, and the between group difference narrowed after continued follow-up. It is thus
plausible that the lack of effect of weight loss and sodium reduction on VVV of BP could be
attributed to the reduced efficacy of lifestyle interventions over time. However, there were
several findings from our study that do not support this hypothesis. First, no differences
were found between the intervention groups and the usual care group when VVVFU was
estimated using visits from the first half of the trial (6 months, 12 months and 18 months)
when the largest effects of the interventions on mean BP were observed. Similarly, there
were no differences between the groups at 18 months when VVV of BP was expressed as
the SD of BP during each follow-up period (VVVbaseline, VVV18mo, and VVV36mo).
Finally, no differences were found between individuals who successfully met intervention
goals for weight loss and sodium reduction compared to individuals who did not, suggesting
that lifestyle interventions did not affect VVV of BP even in the individuals who achieved
the greatest lifestyle changes.
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An interesting finding from our within-subject analyses was that participants who lost
weight initially and then subsequently regained weight (i.e. relapsers) had significantly
higher VVV of BP over the follow-up period (VVVFU) compared to those who did not lose
weight. This phenomenon of weight loss followed by weight gain, commonly referred to as
weight cycling, has been implicated with many deleterious outcomes including
cardiovascular mortality27–29. It has been proposed that the enhanced cardiovascular risk
with weight cycling is, in part, the result of fluctuations in certain risk parameters, including
BP30. Here we showed that VVV of BP was higher in individuals who went through a
period of weight loss and weight regain that is akin to a single weight cycle. We also found
that the VVVFU in body weight was significantly associated with VVVFU of SBP and DBP
among the entire study sample. Taken together, these findings suggest that body weight
fluctuations may, in part, contribute to VVV of BP. However, these results should be
interpreted with caution. First, these results were exploratory analyses and were not based on
intention-to-treat. Second, the magnitude of the difference in VVVFU of BP between the
relapse and no loss groups was modest (SBP: 0.8 ± 0.2 mmHg; DBP: 0.6 ± 0.2 mmHg).
Finally, VVV of BP did not significantly differ over time between any of the achieved
weight loss groups in a fully adjusted model when VVV of BP was quantified using visits at
shorter intervals at baseline, 18 months, and 36 months.
Several limitations must be noted when interpreting our findings. First, as the study
population consisted of relatively young, non-hypertensive participants without substantial
medical co-morbidities, our findings may not be generalizable to older populations with
cardiovascular risk factors or prevalent cardiovascular disease. However, some evidence
suggests that the association between VVV of BP and risk of cardiovascular events is
stronger in younger individuals with BP levels in the normal range4,5, although not all
studies have shown this association31. Thus, the results of the present study may be
generalizable to individuals in whom the strongest associations between VVV of BP and
cardiovascular risk have been observed. Second, as the study population was restricted to
individuals with high-normal DBP, our findings may not be generalizable to individuals
with high-normal SBP levels. However, a large proportion of the study population had
baseline SBP levels in the prehypertensive range. Third, our study was a secondary analysis
of TOHP II, restricted to participants with complete BP data. Therefore, there may have
been selection bias in our analyses, which led to lack of an effect of the behavioral
interventions on VVV of BP. However, a balance in sociodemographic and clinical
characteristics remained present across randomization groups and the effects of the
interventions on mean BP in our study are similar to those reported in the main study.
Finally, BP measurements were obtained using a random zero sphygmomanometer, a device
that some studies have suggested may underestimate BP levels32. However, the randomized
controlled design of our study ensured that any measurement error in BP was not isolated to
a single study group. Moreover, the effects of the interventions on mean BP in our study are
highly consistent with prior studies, demonstrating the internal validity of our findings.
To our knowledge, this is one of the first studies to examine the effects of weight loss and
sodium reduction on VVV of BP. Other major strengths of the study are the randomized
controlled design of TOHP II, a large sample size for a lifestyle modification trial (one of
the largest ever conducted), long-term follow-up, measurement of 24-hour urinary sodium
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excretion levels, and the availability of evenly spaced visits for the estimation of VVV of BP
over the 36-month follow-up period and during three distinct time periods (baseline, 18-
months, 36-months) for repeated measures of VVV of BP. Finally, although TOHP II was
conducted nearly 20 years ago prior to widespread antihypertensive medication use, analysis
of TOHP II data allowed us to uniquely evaluate the effects of weight loss and sodium
reduction on VVV of BP, independent of medication use, in the context of a large
randomized controlled trial of lifestyle interventions which remain clinically relevant today
for individuals with borderline-elevated BP.
In conclusion, our results show that weight loss and sodium reduction, alone or in
combination, did not reduce VVV of BP in overweight adults with high-normal DBP. These
findings suggest that the cardiovascular benefits conferred by weight loss and sodium
reduction may be tied to reductions in mean BP or other non-BP effects, and not to VVV of
BP. Future studies should confirm our findings in higher risk populations including older
adults, patients with hypertension, and those with multiple comorbidities. Studies should
also determine whether interventions that reduce VVV of BP lead to a reduction in
subsequent cardiovascular events. Finally, investigations may also be needed to elucidate the
mechanisms underlying VVV of BP in order to provide direction for the development of
targeted therapies for reducing VVV of BP. Although exploratory in nature, the results of
our study suggest that fluctuations in body weight may be a physiologic mechanism
contributing to VVV of BP. Further research is warranted to confirm these findings.
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Baseline and follow-up visits at which blood pressure (BP) measurements were obtained in
TOHP II, and the estimation of visit-to-visit variability (VVV) in the current study. Upper
panel shows when BP measurements (●) were obtained in TOHP II. The grey boxes in the
middle panel show the visits used to calculate VVV of BP using follow-up visits performed
every 6 months (VVVFU). The grey boxes in the lower panel show the visits used to
calculate VVV of BP using visits performed at shorter intervals at baseline (VVVbaseline),
18-months (VVV18mo) and 36-months (VVV36mo).
DIAZ et al. Page 13
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Hypertens. Author manuscript; available in PMC 2015 April 01.
